-$0.06 EPS Expected for AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) This Quarter

Brokerages expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to post ($0.06) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for AVEO Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.09) and the highest is ($0.04). AVEO Pharmaceuticals posted earnings of ($0.03) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 100%. The company is expected to announce its next earnings results on Thursday, March 12th.

On average, analysts expect that AVEO Pharmaceuticals will report full-year earnings of $0.03 per share for the current financial year, with EPS estimates ranging from $0.00 to $0.06. For the next year, analysts forecast that the company will report earnings of ($0.16) per share, with EPS estimates ranging from ($0.19) to ($0.12). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for AVEO Pharmaceuticals.

AVEO Pharmaceuticals (NASDAQ:AVEO) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.09. The business had revenue of $25.72 million during the quarter. AVEO Pharmaceuticals had a net margin of 120.85% and a negative return on equity of 561.43%.

A number of brokerages have issued reports on AVEO. TheStreet upgraded AVEO Pharmaceuticals from a “d-” rating to a “c-” rating in a research report on Wednesday, November 20th. Piper Jaffray Companies dropped their target price on AVEO Pharmaceuticals from $4.00 to $2.00 and set an “overweight” rating for the company in a report on Monday, November 4th. ValuEngine cut AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Finally, HC Wainwright reissued a “buy” rating and set a $1.75 target price on shares of AVEO Pharmaceuticals in a research report on Tuesday, October 1st. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $1.92.

AVEO traded down $0.02 on Tuesday, hitting $0.74. The company had a trading volume of 1,682,662 shares, compared to its average volume of 4,049,819. The business’s fifty day simple moving average is $0.74 and its 200 day simple moving average is $0.74. The company has a quick ratio of 2.87, a current ratio of 2.87 and a debt-to-equity ratio of 0.46. AVEO Pharmaceuticals has a 12-month low of $0.47 and a 12-month high of $2.14. The company has a market cap of $118.95 million, a PE ratio of -3.89 and a beta of 0.71.

In other news, CEO Michael P. Bailey purchased 150,000 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The shares were bought at an average cost of $0.60 per share, for a total transaction of $90,000.00. Following the acquisition, the chief executive officer now owns 318,848 shares of the company’s stock, valued at approximately $191,308.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.80% of the stock is currently owned by insiders.

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in AVEO Pharmaceuticals by 26.7% during the 2nd quarter. Vanguard Group Inc. now owns 7,670,096 shares of the biopharmaceutical company’s stock valued at $5,164,000 after buying an additional 1,614,802 shares in the last quarter. Cetera Advisor Networks LLC purchased a new position in shares of AVEO Pharmaceuticals during the second quarter worth approximately $38,000. Morgan Stanley raised its stake in shares of AVEO Pharmaceuticals by 265.4% during the second quarter. Morgan Stanley now owns 399,742 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 290,354 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of AVEO Pharmaceuticals during the second quarter valued at approximately $98,000. Finally, NEA Management Company LLC raised its stake in shares of AVEO Pharmaceuticals by 20.8% during the second quarter. NEA Management Company LLC now owns 25,243,865 shares of the biopharmaceutical company’s stock valued at $16,913,000 after acquiring an additional 4,347,827 shares in the last quarter. 26.54% of the stock is owned by hedge funds and other institutional investors.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Further Reading: What are the qualifications of a portfolio manager?

Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.